Synergy Pharmaceuticals

Synergy’s Trulance FDA approved for chronic idiopathic constipation

Monday, January 23, 2017

The FDA has approved Synergy Pharmaceuticals’ Trulance (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC). Trulance is the first drug designed to replicate the function of uroguanylin, a naturally occurring and endogenous human gastrointestinal (GI) peptide that is thought to stimulate fluid secretion which results in a stool consistency associated with more regular bowel function.

[Read More]